HR+/HER2-乳腺癌与HR+/HER2+乳腺癌临床特征和内分泌治疗时长的比较★

Comparison of clinical features and total endocrine therapy duration between HR+/HER2- and HR+/HER2+ breast cancer patients★

摘要:

目的 比较免疫组化激素受体阳性、人表皮生长因子阴性（HR+/HER2-）乳腺癌患者和激素受体阳性、人表皮生长因子受体阳性（HR+/HER2+）乳腺癌患者的临床特征和内分泌治疗时长。方法 回顾性分析青岛大学附属医院收治的36例HR+/HER2-乳腺癌患者和22例HR+/HER2+乳腺癌患者的临床资料，比较两组患者的年龄、月经状态、骨转移、肺转移、肝转移、淋巴结转移、总转移数、BMI、BI-RADS分级、ECOG评分，以及总线数、一线、二线、三线及以上内分泌治疗时长。结果 两组患者年龄、月经状态、肺转移、肝转移、淋巴结转移、总转移数、BMI、BI-RADS分级、ECOG评分，以及总线数、一线、二线、三线及以上内分泌治疗时长比较，差异均无统计学意义（P>0.05）；HR+/HER2+组患者骨转移发生率高于HR+/HER2-组（P<0.05），HR+/HER2-组患者三线及以上内分泌治疗时长长于HR+/HER2+组（P<0.05）。结论 HR+/HER2+乳腺癌可积极选用内分泌治疗或与HER2靶向药物联合治疗，从而避免使用化疗，减轻化疗所带来的不良反应。

Abstract:

Objective To compare the clinical features and the total duration of endocrine therapy between immunohistochemical hormone receptor positive and human epidermal growth factor negative groups (HR+/HER2-) and hormone receptor positive and human epidermal growth factor receptor positive groups (HR+/HER2+).Methods The clinical features of 58 cases of breast cancer treated in the Affiliated Hospital of Qingdao University were analyzed retrospectively, including 36 cases of HR+/HER2- and 22 cases of HR+/HER2+. The age, menstrual status, bone metastasis, lung metastasis, liver metastasis, lymph node metastasis, total number of metastases, BMI, BI-RADS grade, ECOG score and total endocrine therapy duration, first-line endocrine therapy duration, second-line endocrine therapy duration, third-line and above endocrine therapy duration were compared between the two groups.Results There were no statistical differences between the two groups in age, menstrual status, lung metastasis, liver metastasis, lymph node metastasis, total metastasis, BMI, BI-RADS grade, ECOG score, total endocrine therapy duration, first-line endocrine therapy duration and second-line endocrine therapy duration (P>0.05). The incidence of bone metastasis in HR+/HER2+ group was higher than that in HR+/HER2- group, and the duration of third-line and above endocrine therapy in HR+/HER2- group was longer than that in HR+/HER2+ group, with statistical significance (P<0.05).Conclusion HR+/HER2+ breast cancer can be actively treated with endocrine therapy or in combination with HER2-targeted drugs, so as to avoid the use of chemotherapy and reduce the adverse reactions caused by chemotherapy.